Sofinnova Partners Raises €650M To Support Biopharma And MedTech Innovation

Based in Paris, London, and Milan, Sofinnova Capital XI will support a new generation of biopharmaceutical and medical technology companies addressing urgent unmet clinical needs. The fund is already deploying capital, with early investments in Latent Labs, BioCorteX, and Amolyt.

Aligned with Sofinnova’s multi-strategy platform, Capital XI leverages the expertise of its experienced team, including Partners Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter, and Graziano Seghezzi.

The fund attracted strong backing from blue-chip institutional investors worldwide, including sovereign wealth funds, pharmaceutical companies, corporates, insurance companies, foundations, and family offices, spanning Europe, North America, Asia and the Middle East. A mix of returning LPs and new top-tier investors reflects enduring confidence in Sofinnova’s disciplined strategy and proven track record.

Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, said:

“This fundraising marks a pivotal moment for Sofinnova. It gives us the firepower to double down on early-stage opportunities and reinforces our uniquely collaborative, science-driven investment approach.

We’re excited to continue backing visionary entrepreneurs and advancing the next wave of breakthroughs in science and medicine to bring them to patients worldwide."

The fund will continue backing early-stage biotech and medtech companies across Europe and North America, participating in both initial investments and follow-on financing rounds.

About Sofinnova Partners

Sofinnova Partners, founded in 1972, is a leading European life sciences venture capital firm specializing in healthcare and sustainability. With offices in Paris, London and Milan, it partners with entrepreneurs across all stages, building transformative companies. The firm manages over €4 billion and has backed 500+ global market leaders.